MENLO PARK, Calif., April 17, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed a Type B pre-NDA meeting with the United States Food and Drug Administration (FDA) regarding the results of the three Phase 3 clinical trials of Serada® (extended-release gabapentin tablets), Depomed’s investigational gastric-retentive, extended-release formulation of gabapentin for menopausal hot flashes. Based on the results of the meeting with the FDA, Depomed intends to prepare and file a new drug application with the FDA in the second half of 2012.
